Statement from Dechra re. Zycortal April 2016

Statement:

At Dechra Veterinary Products we understand the challenging nature of the diagnosis and management of canine Addison’s disease.

To assist in the management of this complex condition, we have recently launched a new injectable POM-V (Prescription Only Medicine-Veterinarian) product licensed for dogs with Addison’s disease.

The new product is a prolonged release suspension for injection which provides the confidence that Addison’s disease will be controlled for the duration of approximately one month following each injection.

It is efficacious, well tolerated and allows tailored dosing for each dog with Addison’s disease. A daily tablet will also be needed to help replace the cortisol.

Following the UK launch at the start of April 2016, we are committed to raising awareness of the product amongst the veterinary profession.

We are engaged in a series of activities with veterinary professionals which include; exhibiting at the UK’s largest veterinary congress, print and online advertising in the veterinary press and availability of diagnosis and treatment support tools for veterinary surgeons in print and digital formats. As you can appreciate, it will take a little time for the information to be disseminated but we are passionate about increasing awareness of Addison’s disease.

Our Technical Team is manned by a number of vets with a significant amount of first opinion practice experience and are in frequent contact with some of Europe’s leading experts on the treatment of Addison’s. They work with vets on a daily basis to provide support and knowledge to vets treating dogs with Addison’s.

Any questions about your dog should be directed to your veterinary practice.
Craig Sankey
Brand Manager, Strategic Brands
Marketing
Dechra Veterinary Products Ltd